Loading
GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.
GQ1005 is an antibody-drug conjugate developed by GeneQuantum Healthcare (Suzhou). Its target is HER2 (the sponsor names HER2). The sponsor states: A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673029 (A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer), in HER2-positive breast cancer. The largest, NCT07673029, plans to enrol 228 participants with primary completion expected 2027-01-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload. Connects to HER2.
1.GQ1005's antibody arm binds HER2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GQ1005" OR ABSTRACT:"GQ1005") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GQ1005, not a curated reading list.
Shares GeneQuantum Healthcare (Suzhou) and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.